ARS Pharmaceuticals Inc
SPRY7.590USD
+0.860+12.78%
收盤 11/21, 16:00（美東）報價延遲15分鐘
750.23M總市值
虧損本益比TTM
關於 ARS Pharmaceuticals Inc 公司
ARS Pharmaceuticals, Inc. 是一家生物製藥公司。該公司專注於開發 neffy，用於緊急治療 I 型過敏反應，包括過敏反應。neffy 是一種專有的腎上腺素組合物，含有一種名爲 Intravail 的吸收促進劑，可使 neffy 以小劑量、小劑量和鼻腔噴霧的形式提供類似注射的腎上腺素吸收。I 型過敏反應是可能危及生命的超敏反應，可能在接觸過敏原幾分鐘內發生，需要立即治療以緩解症狀並防止進一步發展。
ARS Pharmaceuticals Inc簡介
公司代碼SPRY
公司名稱ARS Pharmaceuticals Inc
上市日期Dec 04, 2020
CEOMr. Richard E. Lowenthal
員工數量155
證券類型Ordinary Share
年結日Dec 04
公司地址11682 El Camino Real, Suite 120
城市SAN DIEGO
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編92130
電話18587719307
網址https://ars-pharma.com/
公司代碼SPRY
上市日期Dec 04, 2020
CEOMr. Richard E. Lowenthal
ARS Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.83M
-14.34%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
4.57M
-10.85%
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
86.26K
-3.33%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--
Dr. Rajeev Dadoo, Ph.D.
Dr. Rajeev Dadoo, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kathleen D. (Kathy) Scott
Ms. Kathleen D. (Kathy) Scott
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Pratik Shah, Ph.D.
Dr. Pratik Shah, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Mr. Brenton L. (Brent) Saunders, J.D.
Mr. Brenton L. (Brent) Saunders, J.D.
Director
Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.83M
-14.34%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
4.57M
-10.85%
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
86.26K
-3.33%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
RA Capital Management, LP
10.99%
OrbiMed Advisors, LLC
8.39%
Deerfield Management Company, L.P.
7.59%
Lowenthal (Richard E)
6.91%
Pratik Shah Living Trust
4.88%
其他
61.25%
持股股東
持股股東
佔比
RA Capital Management, LP
10.99%
OrbiMed Advisors, LLC
8.39%
Deerfield Management Company, L.P.
7.59%
Lowenthal (Richard E)
6.91%
Pratik Shah Living Trust
4.88%
其他
61.25%
股東類型
持股股東
佔比
Hedge Fund
22.20%
Investment Advisor/Hedge Fund
19.53%
Investment Advisor
16.81%
Venture Capital
15.19%
Individual Investor
11.94%
Private Equity
8.39%
Corporation
4.88%
Research Firm
3.80%
Insurance Company
0.59%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
381
87.74M
88.78%
-2.41M
2025Q2
367
96.00M
97.76%
-11.66M
2025Q1
380
100.63M
102.48%
-12.75M
2024Q4
345
96.62M
99.42%
-14.07M
2024Q3
320
88.19M
90.90%
-18.52M
2024Q2
291
87.17M
89.94%
-20.35M
2024Q1
289
89.45M
92.60%
-16.44M
2023Q4
280
92.18M
96.08%
-6.49M
2023Q3
283
95.82M
104.35%
+1.21M
2023Q2
278
88.26M
96.94%
-730.20K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
RA Capital Management, LP
10.94M
11.07%
+80.00K
+0.74%
Sep 29, 2025
OrbiMed Advisors, LLC
8.29M
8.39%
--
--
Jun 30, 2025
Deerfield Management Company, L.P.
7.61M
7.7%
-2.11M
-21.74%
Jul 30, 2025
Lowenthal (Richard E)
6.83M
6.91%
-1.14M
-14.34%
Mar 31, 2025
Pratik Shah Living Trust
4.82M
4.88%
--
--
Mar 31, 2025
Tanimoto (Sarina)
4.57M
4.63%
-556.66K
-10.85%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.93M
3.98%
+47.01K
+1.21%
Jun 30, 2025
SR One Capital Management, LP
4.01M
4.06%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
3.25M
3.29%
-228.66K
-6.57%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
ALPS Medical Breakthroughs ETF
0.62%
First Trust Small Cap Growth AlphaDEX Fund
0.32%
SPDR S&P Biotech ETF
0.31%
VictoryShares US Small Mid Cap Value Momentum ETF
0.18%
Direxion Daily S&P Biotech Bull 3X Shares
0.17%
First Trust Small Cap Core Alphadex Fund
0.16%
Invesco Nasdaq Biotechnology ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.1%
Principal U.S. Small-Cap ETF
0.08%
First Trust Multicap Growth Alphadex Fund
0.07%
查看更多
ALPS Medical Breakthroughs ETF
佔比0.62%
First Trust Small Cap Growth AlphaDEX Fund
佔比0.32%
SPDR S&P Biotech ETF
佔比0.31%
VictoryShares US Small Mid Cap Value Momentum ETF
佔比0.18%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.17%
First Trust Small Cap Core Alphadex Fund
佔比0.16%
Invesco Nasdaq Biotechnology ETF
佔比0.1%
ProShares Ultra Nasdaq Biotechnology
佔比0.1%
Principal U.S. Small-Cap ETF
佔比0.08%
First Trust Multicap Growth Alphadex Fund
佔比0.07%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
ARS Pharmaceuticals Inc的前五大股東是誰？
ARS Pharmaceuticals Inc的前五大股東如下：
RA Capital Management, LP持有股份：10.94M佔總股份比例：11.07%。
OrbiMed Advisors, LLC持有股份：8.29M佔總股份比例：8.39%。
Deerfield Management Company, L.P.持有股份：7.61M佔總股份比例：7.70%。
Lowenthal (Richard E)持有股份：6.83M佔總股份比例：6.91%。
Pratik Shah Living Trust持有股份：4.82M佔總股份比例：4.88%。
RA Capital Management, LP持有股份：10.94M佔總股份比例：11.07%。
OrbiMed Advisors, LLC持有股份：8.29M佔總股份比例：8.39%。
Deerfield Management Company, L.P.持有股份：7.61M佔總股份比例：7.70%。
Lowenthal (Richard E)持有股份：6.83M佔總股份比例：6.91%。
Pratik Shah Living Trust持有股份：4.82M佔總股份比例：4.88%。
ARS Pharmaceuticals Inc的前三大股東類型是什麼？
ARS Pharmaceuticals Inc 的前三大股東類型分別是：
RA Capital Management, LP
OrbiMed Advisors, LLC
Deerfield Management Company, L.P.
RA Capital Management, LP
OrbiMed Advisors, LLC
Deerfield Management Company, L.P.
有多少機構持有ARS Pharmaceuticals Inc(SPRY)的股份？
截至2025Q3，共有381家機構持有ARS Pharmaceuticals Inc的股份，合計持有的股份價值約為87.74M，占公司總股份的88.78% 。與2025Q2相比，機構持股有所增加，增幅為-8.98%。
哪個業務部門對ARS Pharmaceuticals Inc的收入貢獻最大？
在--，--業務部門對ARS Pharmaceuticals Inc的收入貢獻最大，創收--，占總收入的--% 。
